Money left on the table: Generic drug prices in Canada

Healthcare Policy

Volumn 8, Issue 3, 2013, Pages 17-25

  Law, Michael R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BISOPROLOL; GENERIC DRUG; OXAZEPAM; RISPERIDONE; SIMVASTATIN;

CANADA; COST CONTROL; DRUG COST; DRUG MARKETING; DRUG PROGRAM; HUMAN; NEW ZEALAND; ORGANIZATION AND MANAGEMENT; PRESCRIPTION; REVIEW; SENSITIVITY ANALYSIS; UNITED STATES;

CANADA; COST SAVINGS; DRUG COSTS; DRUGS, GENERIC; FORMULARIES AS TOPIC; HUMANS; NEW ZEALAND; ONTARIO; UNITED STATES;

EID: 84875486211     PISSN: None     EISSN: 17156572     Source Type: Journal    
DOI: 10.12927/hcpol.2013.23208     Document Type: Review

References (27)

1. Bank of Canada. 2011. Monthly and Annual Average Exchange Rates. Retrieved December 19, 2012. .
2. Board on Health Care Services. 2000. Description and Analysis of the VA National Formulary. Washington, DC: Institute of Medicine. Retrieved December 19, 2012. .
3. Canadian Generic Pharmaceutical Association. 2011. "Release of Canadian rescription Drug Sales Information Highlights Increasing Value of Generic Medicines." Retrieved December 19, 2012.
4. Canadian Institute for Health Information (CIHI). 2011. Health Care Cost Drivers: The Facts. Ottawa: Author. Retrieved December 19, 2012. .
5. Competition Bureau Canada. 2007. Generic Drug Sector Study. Ottawa: Government of Canada. Retrieved December 19, 2012. .
6. Competition Bureau Canada. 2008. Benefiting from Generic Drug Competition in Canada: The Way Forward. Ottawa: Government of Canada. Retrieved December 19, 2012. .
7. Dhalla, I., M. Smith, N. Choudhry and A. Denburg. 2009. "Costs and Benefits of Free Medications After Myocardial Infarction." Healthcare Policy 5(2): 68-86.
8. Government of British Columbia. 2012 (February 29). "Lower Drug Prices to Benefit Patients, Health System." News release. Retrieved December 19, 2012. .
9. Government of Ontario. 2011. Ontario Drug Benefit Formulary/Comparative Drug Index. Retrieved December 19, 2012. .
10. Guertin, J.R., C.A. Jackevicius, J.L. Cox, K. Humphries, L. Pilote, D.Y. So et al. 2011. "The Potential Economic Impact of Restricted Access to Angiotensin-Receptor Blockers." Canadian Medical Association Journal 183(3): e180-e186. doi: 10.1503/cmaj.100787.
11. IMS Brogan. 2011. "Generic Dispensing Trends by Province, Canada, 2010." Retrieved December 19, 2012. .
12. IMS Health. 2011. "IMS Institute Reports US Spending on Medicines Grew 2.3 Percent in 2010, to $307.4 Billion." Retrieved May 5, 2011. .
13. Jackevicius, C.A., J.L. Cox, D. Carreon, J.V. Tu, S. Rinfret, D. So et al. 2009. "Long-Term Trends in Use of and Expenditures for Cardiovascular Medications in Canada." Canadian Medical Association Journal 181(1-2): e19-e28. doi: 10.1503/cmaj.081913.
14. Kesselheim, A.S., A.S. Misono, J.L. Lee, M.R. Stedman, M.A. Brookhart, N.K. Choudhry et al. 2008. "Clinical Equivalence of Generic and Brand-Name Drugs Used in Cardiovascular Disease: A Systematic Review and Meta-Analysis." Journal o the American Medical Association 300(21): 2514-26. doi: 10.1001/jama.2008.758.
15. Law, M.R., L. Cheng, I.A. Dhalla, D. Heard and S.G. Morgan. 2012. "The Effect of Cost on Adherence to Prescription Medications in Canada." Canadian Medical Association Journal 184(3): 297-302. doi: 10.1503/cmaj.111270.
16. Law, M.R. and J. Kratzer. 2012. "The Road to Competitive Generic Drug Prices in Canada." Canadian Medical Association Journal. doi: 10.1503/cmaj.121367.
17. Law, M.R. and S.G. Morgan. 2011. "Purchasing Prescription Drugs in Canada: Hang Together or Hang Separately." Healthcare Policy 6(4): 22-26.
18. Morgan, S., G. Hanley, M. McMahon and M. Barer. 2007. "Influencing Drug Prices through Formulary-Based Policies: Lessons from New Zealand." Healthcare Policy 3(1): 1-20.
19. Morgan, S.G. 2004. "Sources of Variation in Provincial Drug Spending." Canadian Medical Association Journal 170(3): 329-30.
20. Morgan, S.G., M.L. Barer and J.D. Agnew. 2003. "Whither Seniors' Pharmacare: Lessons from (and for) Canada." Health Affairs 22(3): 49-59. doi: 10.1377/hlthaff.22.3.49. (Pubitemid 41388744)
21. Moulton, D. 2011. "Provincial Squeeze on Generic Prices Continues." Canadian Medical Association Journal 183(14): e1049- e1050. doi: 10.1503/cmaj.109-3966.
22. New Zealand Pharmaceutical Management Agency. 2011. "Purchasing Medicines." Retrieved December 19, 2012. .
23. Patented Medicine Prices Review Board (PMPRB). 2006. Non-Patented Prescription Drug Prices Reporting: Canadian and Foreign Price Trends. Ottawa: Author.
24. Patented Medicine Prices Review Board (PMPRB). 2010. Generic Drugs in Canada: Price Trends and International Comparisons, 2007. Ottawa: Author. Retrieved December 19, 2012. .
25. Pharmaceutical Management Agency. 2011. Online Schedule. Retrieved December 19, 2012. .
26. Pharmacy Benefits Management Services. 2012. Drug Pharmaceutical Prices. Washington: US Department of Veterans Affairs. Retrieved December 19, 2012. .
27. Secor Consulting. 2010. Generic Drug Pricing and Access in Canada: What Are the Implications? Toronto: Health Council of Canada.